Market by Therapeutics, Diagnostics, and Regional Outlook | Forecast 2022-2028
Alzheimer’s disease
(AD) is a progressive, degenerative condition that affects the brain’s neurons
and causes memory loss, behavioral abnormalities, and thinking & language
impairments. The rising prevalence of this disease is posing a serious threat
to the public’s health. There are 5.3 million Alzheimer’s patients in the
United States alone, and 35 million worldwide, as per the Translational
Research & Clinical Interventions journal.
According to Triton Market Research’s analysis, the Global Alzheimer’s Disease Therapeutics and Diagnostics Market is likely to reach $10991.17 million by 2028 from $6703.50 million in 2021, with a CAGR of 6.98% during the forecast period 2022-2028.
Click here to check out our blog on the Global Alzheimer’s Disease Therapeutics and Diagnostics Market
MARKET PERFORMANCE: DRIVERS, CHALLENGES, AND TRENDS
Over
the forecast period, the market’s expansion is likely to be fueled by the
significant increase in Alzheimer’s disease prevalence and the rise in the
older population. Alzheimer’s disease is one of
the most common forms of dementia in the world. A new case of AD is believed to
occur every 33 seconds, which accounts for the disease’s extremely high
frequency and prevalence in almost 35 million people globally. This has
increased the demand to develop clinical diagnostics and therapies for AD and
other neurodegenerative disorders.
The
market, however, faces significant obstacles like the failure of late-stage
medications and strict government regulations. The
cholinergic hypothesis of memory impairment was first put forth in 1984,
marking the beginning of the present age of medication development for AD.
Since then, only 4 cholinesterase inhibitors & memantine have demonstrated
effectiveness against Alzheimer’s progression, despite the study of innumerable
possible treatments & medications in clinical studies. As a result, the
global market for diagnostics and treatments for Alzheimer’s disease has been
considerably constrained by the failures of these late-stage medications.
The usage of computed tomography (CT) in the diagnosis of Alzheimer’s disease presents an overall positive outlook for the market. Computed tomography is one of the most advanced & cost-effective diagnostic tests used for the diagnosis of AD. According to Medscape, a CT scan is nearly 20% less expensive compared to an MRI scan. This has increased the demand for CT scans in the Alzheimer’s affected population.
KEY GEOGRAPHIES COVERED:
• North America: United States and Canada
• Europe: United Kingdom, France,
Germany, Spain, Italy, and Rest of Europe
• Asia-Pacific: China, Japan, India,
Australia, South Korea, ASEAN Countries, and Rest of Asia-Pacific
• Latin America: Brazil, Mexico, and Rest
of Latin America
• Middle East and Africa: Saudi Arabia,
Turkey, United Arab Emirates, South Africa, and Rest of Middle East &
Africa
SEGMENTATION ANALYSIS - ALZHEIMER’S DISEASE THERAPEUTICS
AND DIAGNOSTICS MARKET
• Therapeutics is sub-segmented into:
o By Drug Type
• Marketed
Drugs
• Pipeline
Drugs
o By Disease Stage
• Late
Stage: Severe AD
• Early/Middle
Stage: Mild to Moderate AD
• Prodromal
Stage
o By Generic & Branded
• Branded
• Generic
Cholinesterase inhibitors, NMDA receptor antagonists, and other
medications are marketed drugs in the global Alzheimer’s
disease therapeutics and diagnostics market. The drugs that stop the body from breaking down acetylcholine are known
as cholinesterase inhibitors or acetylcholinesterase inhibitors. Certain nerve
cells have significantly decreased activity in persons with advanced
Alzheimer’s disease. This implies that brain signals may not be sent as
quickly. Cholinesterase inhibitors work to reduce illness symptoms by enhancing
communication between nerve cells.
• Diagnostics is sub-segmented into:
o Lumbar Puncture Test
o Positron Emission Tomography
o Electroencephalography
o Magnetic Resonance Imaging
o Computed Tomography
o Blood Test
o Other Diagnostics
The
diagnosis of Alzheimer’s disease using a blood test presents a significant
market opportunity for diagnostic and treatment products. Alzheimer’s disease
can be avoided with a blood test that can spot the disease in its early stages.
The condition can potentially be treated with medication if AD is detected in
its early stages. Adtect, a newly created blood test, is utilized in the early
identification of AD. The test is known as the AD-specific genes signature test
and is based on assessing the expression of the chosen genes in the blood.
COMPETITIVE LANDSCAPE:
The competitive
landscape helps dive into data about the key players in the Alzheimer’s disease
therapeutics and diagnostics market. The strategic initiatives for each of the
companies considered have been covered in detail.
Collaboration
(July 2021): Eli Lilly and Company collaborated with Banner Alzheimer’s
Institute
Donanemab, an antibody
that acts as a modified form of amyloid A and is being studied for the
treatment of early Alzheimer’s disease, is being tested in a Phase 3 preventive
trial in conjunction with Lilly and the Banner Alzheimer’s Institute.
Product
Development (June 2021): EISAI and Biogen Inc declared FDA grant for LECANEMAB
(BAN2401)
A revolution therapy
designation for LECANEMAB (BAN2401), an anti-amyloid beta proteofibril antibody
for the treatment of Alzheimer’s disease, was announced by EISAI and Biogen
Inc.
Key Benefits of the Report:
· Triton Market Research has a collective experience of 25-30 years in the industry, with its analysts and experts encompassing the most infallible research methodology for its market intelligence and industry analysis.
· Our research methodology helps in achieving a broader consensus of the market size, shape, and industry trends within each industry segment.
· The strategy adopted in designing the research methodology includes the amalgamation of the information assembled from primary and secondary sources, with the assistance of analytical tools to construct the forecast and predictive models.
·
The scope of the market report
comprises the current scenario of the global alzheimer’s disease therapeutics and diagnostic market, along
with the detailed overview of the industry outlook, market dynamics,
segmentation analysis, regional outlook, and competitive landscape for the
period 2022-2028.
FAQs:
Q 1) Does this report include the impact of COVID-19 on the
Alzheimer’s disease therapeutics and diagnostics market?
The market study has
analyzed the impact of COVID-19 on the Alzheimer’s disease therapeutics and
diagnostics market qualitatively as well as quantitatively.
Q 2) Which Alzheimer’s disease type is more prevalent?
The majority of the
market share was held by late stage: severe AD in 2021. According to alz.org,
the US Food and Drug Administration (FDA) has licensed memantine (Namenda)
& cholinesterase inhibitors (Razadyne, Exelon, Aricept) as late-stage
medications to treat cognitive symptoms (confusion, memory loss, and problems
with thinking and reasoning).
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. TIMELINE
OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.2. PHASES
AND STERNNESS OF ALZHEIMER’S DISEASE
2.3. KEY
INSIGHTS
2.3.1. USAGE
OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE
2.3.2. R&D
INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.3.3. DEMAND
FOR PERSONALIZED MEDICINES
2.4. IMPACT
OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.5. PORTER’S
FIVE FORCES ANALYSIS
2.6. MARKET
ATTRACTIVENESS MATRIX
2.7. VENDOR
SCORECARD
2.8. INDUSTRY
COMPONENTS
2.8.1. RESEARCH
& DEVELOPMENT (R & D)
2.8.2. RAW
MATERIALS
2.8.3. MANUFACTURING
2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS
2.8.5. END-USER
2.9. KEY
IMPACT ANALYSIS
2.9.1. EFFECTIVENESS
2.9.2. PRICE
2.9.3. SAFETY
2.10. KEY
MARKET STRATEGIES
2.10.1. ACQUISITIONS
2.10.2. PRODUCT
LAUNCHES
2.10.3. CONTRACTS
& AGREEMENTS
2.10.4. INVESTMENTS
& EXPANSIONS
2.11. MARKET
DRIVERS
2.11.1. PREVALENCE
OF ALZHEIMER’S DISEASE
2.11.2. RISE
IN THE ELDERLY POPULATION
2.12. MARKET
CHALLENGES
2.12.1. FAILURE
OF LATE-STAGE DRUGS
2.12.2. STRINGENT
GOVERNMENT REGULATIONS
2.13. MARKET
OPPORTUNITIES
2.13.1. EMERGENCE
OF NEW DIAGNOSTIC TECHNOLOGIES
2.13.2. GROWING
NUMBER OF PIPELINE DRUGS
3. GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY THERAPEUTICS
3.1. BY
DRUG TYPE
3.1.1. MARKETED
DRUGS
3.1.2. PIPELINE
DRUGS
3.2. BY
DISEASE STAGE
3.2.1. LATE
STAGE: SEVERE AD
3.2.2. EARLY/MIDDLE
STAGE: MILD TO MODERATE AD
3.2.3. PRODROMAL
STAGE
3.3. BY
GENERIC & BRANDED
3.3.1. BRANDED
3.3.2. GENERIC
4. GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY DIAGNOSTICS
4.1. LUMBAR
PUNCTURE TEST
4.2. POSITRON
EMISSION TOMOGRAPHY
4.3. ELECTROENCEPHALOGRAPHY
4.4. MAGNETIC
RESONANCE IMAGING
4.5. COMPUTED
TOMOGRAPHY
4.6. BLOOD
TEST
4.7. OTHER
DIAGNOSTICS
5. GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – REGIONAL OUTLOOK
5.1. NORTH
AMERICA
5.1.1. MARKET
BY THERAPEUTICS
5.1.1.1. MARKET
BY DRUG TYPE
5.1.1.2. MARKET
BY DISEASE STAGE
5.1.1.3. MARKET
BY GENERIC & BRANDED
5.1.2. MARKET
BY DIAGNOSTICS
5.1.3. COUNTRY
ANALYSIS
5.1.3.1. UNITED
STATES
5.1.3.2. CANADA
5.2. EUROPE
5.2.1. MARKET
BY THERAPEUTICS
5.2.1.1. MARKET
BY DRUG TYPE
5.2.1.2. MARKET
BY DISEASE STAGE
5.2.1.3. MARKET
BY GENERIC & BRANDED
5.2.2. MARKET
BY DIAGNOSTICS
5.2.3. COUNTRY
ANALYSIS
5.2.3.1. UNITED
KINGDOM
5.2.3.2. GERMANY
5.2.3.3. FRANCE
5.2.3.4. ITALY
5.2.3.5. SPAIN
5.2.3.6. REST
OF EUROPE
5.3. ASIA-PACIFIC
5.3.1. MARKET
BY THERAPEUTICS
5.3.1.1. MARKET
BY DRUG TYPE
5.3.1.2. MARKET
BY DISEASE STAGE
5.3.1.3. MARKET
BY GENERIC & BRANDED
5.3.2. MARKET
BY DIAGNOSTICS
5.3.3. COUNTRY
ANALYSIS
5.3.3.1. CHINA
5.3.3.2. JAPAN
5.3.3.3. INDIA
5.3.3.4. SOUTH
KOREA
5.3.3.5. ASEAN
COUNTRIES
5.3.3.6. AUSTRALIA
AND NEW ZEALAND
5.3.3.7. REST
OF ASIA-PACIFIC
5.4. LATIN
AMERICA
5.4.1. MARKET
BY THERAPEUTICS
5.4.1.1. MARKET
BY DRUG TYPE
5.4.1.2. MARKET
BY DISEASE STAGE
5.4.1.3. MARKET
BY GENERIC & BRANDED
5.4.2. MARKET
BY DIAGNOSTICS
5.4.3. COUNTRY
ANALYSIS
5.4.3.1. BRAZIL
5.4.3.2. MEXICO
5.4.3.3. REST
OF LATIN AMERICA
5.5. MIDDLE
EAST AND AFRICA
5.5.1. MARKET
BY THERAPEUTICS
5.5.1.1. MARKET
BY DRUG TYPE
5.5.1.2. MARKET
BY DISEASE STAGE
5.5.1.3. MARKET
BY GENERIC & BRANDED
5.5.2. MARKET
BY DIAGNOSTICS
5.5.3. COUNTRY
ANALYSIS
5.5.3.1. UNITED
ARAB EMIRATES
5.5.3.2. TURKEY
5.5.3.3. SAUDI
ARABIA
5.5.3.4. SOUTH
AFRICA
5.5.3.5. REST
OF MIDDLE EAST & AFRICA
6. COMPETITIVE
LANDSCAPE
6.1. BAXTER
INTERNATIONAL INC
6.2. F.
HOFFMANN-LA ROCHE AG
6.3. ALLERGAN
PLC (ACQUIRED BY ABBVIE)
6.4. NOVARTIS
AG
6.5. PFIZER
INC
6.6. SIEMENS
HEALTHINEERS AG
6.7. AMARANTUS
BIOSCIENCE HOLDINGS INC
6.8. EISAI
CO LTD
6.9. ELI
LILLY & COMPANY
6.10. LUPIN
LIMITED
6.11. MERCK
AND CO
6.12. BIOGEN
INC
6.13. COGNOPTIX
INC
6.14. GE
HEALTHCARE
6.15. JOHNSON
AND JOHNSON
6.16. SUN
PHARMACEUTICALS INDUSTRIES LTD
6.17. TEVA
PHARMACEUTICAL INDUSTRIES LTD
6.18. ZYDUS
CADILA
7. METHODOLOGY
& SCOPE
7.1. RESEARCH
SCOPE
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE 1: MARKET
ATTRACTIVENESS MATRIX
TABLE 2: VENDOR
SCORECARD
TABLE 3: KEY STRATEGIC
DEVELOPMENTS
TABLE 4: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS,
2022-2028 (IN $ MILLION)
TABLE 5: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 6: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $
MILLION)
TABLE 7: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028
(IN $ MILLION)
TABLE 8: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS,
2022-2028 (IN $ MILLION)
TABLE 9: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK,
2022-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK,
2022-2028 (IN $ MILLION)
TABLE 11: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS,
2022-2028 (IN $ MILLION)
TABLE 12: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 13: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $
MILLION)
TABLE 14: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028
(IN $ MILLION)
TABLE 15: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS,
2022-2028 (IN $ MILLION)
TABLE 16: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK,
2022-2028 (IN $ MILLION)
TABLE 17: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS,
2022-2028 (IN $ MILLION)
TABLE 18: EUROPE ALZHEIMER’S
DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 19: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $
MILLION)
TABLE 20: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028
(IN $ MILLION)
TABLE 21: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS,
2022-2028 (IN $ MILLION)
TABLE 22: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK,
2022-2028 (IN $ MILLION)
TABLE 23: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS,
2022-2028 (IN $ MILLION)
TABLE 24: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 25: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $
MILLION)
TABLE 26: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028
(IN $ MILLION)
TABLE 27: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS,
2022-2028 (IN $ MILLION)
TABLE 28: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK,
2022-2028 (IN $ MILLION)
TABLE 29: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS,
2022-2028 (IN $ MILLION)
TABLE 30: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 31: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $
MILLION)
TABLE 32: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028
(IN $ MILLION)
TABLE 33: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS,
2022-2028 (IN $ MILLION)
TABLE 34: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY
OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 35: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE 36: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN
$ MILLION)
TABLE 37: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028
(IN $ MILLION)
TABLE 38: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED,
2022-2028 (IN $ MILLION)
TABLE 39: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
DIAGNOSTICS, 2022-2028 (IN $ MILLION)
FIGURE 1: PORTER’S FIVE
FORCES ANALYSIS
FIGURE 2: KEY IMPACT
ANALYSIS
FIGURE 3: TIMELINE OF
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
FIGURE 4: INDUSTRY
COMPONENTS
FIGURE 5: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021
& 2028 (IN %)
FIGURE 6: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021 & 2028 (IN %)
FIGURE 7: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2028 (IN $
MILLION)
FIGURE 8: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2028 (IN $
MILLION)
FIGURE 9: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021 & 2028 (IN
%)
FIGURE 10: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2022-2028 (IN
$ MILLION)
FIGURE 11: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO
MODERATE AD, 2022-2028 (IN $ MILLION)
FIGURE 12: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2028 (IN $
MILLION)
FIGURE 13: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2021 &
2028 (IN %)
FIGURE 14: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $ MILLION)
FIGURE 15: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $ MILLION)
FIGURE 16: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2021
& 2028 (IN %)
FIGURE 17: GLOBAL
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2028 (IN
$ MILLION)
FIGURE 18: GLOBAL
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY,
2022-2028 (IN $ MILLION)
FIGURE 19: GLOBAL
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2028
(IN $ MILLION)
FIGURE 20: GLOBAL
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING,
2022-2028 (IN $ MILLION)
FIGURE 21: GLOBAL
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2028 (IN $
MILLION)
FIGURE 22: GLOBAL
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN $ MILLION)
FIGURE 23: GLOBAL
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2028 (IN $
MILLION)
FIGURE 24: GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021
& 2028 (IN %)
FIGURE 25: UNITED
STATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 26: CANADA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 27: UNITED
KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 28: GERMANY
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 29: FRANCE
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 30: ITALY
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 31: SPAIN
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 32: REST OF
EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 33: CHINA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 34: JAPAN
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 35: INDIA ALZHEIMER’S
DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 36: SOUTH KOREA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 37: ASEAN
COUNTRIES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN
$ MILLION)
FIGURE 38: AUSTRALIA
& NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2022-2028 (IN $ MILLION)
FIGURE 39: REST OF
ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028
(IN $ MILLION)
FIGURE 40: BRAZIL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 41: MEXICO
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 42: REST OF
LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028
(IN $ MILLION)
FIGURE 43: UNITED ARAB
EMIRATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN
$ MILLION)
FIGURE 44: SAUDI ARABIA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 45: TURKEY
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 46: SOUTH AFRICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 47: REST OF
MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
MARKET 2022-2028 (IN $ MILLION)